期刊
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
卷 15, 期 4, 页码 302-306出版社
WILEY
DOI: 10.1111/j.1529-8027.2010.00283.x
关键词
antibodies; ganglioside complexes; GQ1b; IgM; MAG; monoclonal gammopathy; neuropathy; rituximab; sulfatide
Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin-associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据